New cholesterol guidelines push earlier treatment, better risk calculators, and lower LDL targets

One in four American adults has elevated LDL cholesterol. Most of them do not know their precise risk of heart attack or stroke - in part because the risk calculator their doctors have been using overestimates that risk by 40% to 50%.

That changes with a major guideline update published March 13 by the American College of Cardiology, the American Heart Association, and nine partner medical organizations. The document, jointly released in JACC and Circulation, consolidates evidence-based lipid management into a single resource and introduces several meaningful shifts in how clinicians should assess and treat dyslipidemia - abnormal levels of cholesterol and triglycerides in the blood.

Out with the old risk calculator

The most immediate practical change is the adoption of the PREVENT-ASCVD equations, replacing the older Pooled Cohort Equations for primary prevention risk assessment. Designed for adults ages 30 to 79 without known cardiovascular disease, PREVENT estimates both 10-year and 30-year risk of heart attack or stroke using data routinely collected during annual physicals: cholesterol, blood pressure, age, and health habits.

The old equations overestimated 10-year risk by 40% to 50%, according to Roger Blumenthal, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease. Overestimation might sound like it would lead to more aggressive treatment, but in practice it eroded clinical confidence in the scores and may have led some physicians to dismiss borderline results.

The updated risk categories classify 10-year ASCVD risk as low (below 3%), borderline (3% to under 5%), intermediate (5% to under 10%), and high (10% or above). These tiers guide decisions on whether to initiate statin therapy and at what intensity.

Lower LDL targets, earlier intervention

The guideline reinstates specific LDL-C and non-HDL-C goals - a feature that had been deemphasized in previous editions. For primary prevention in borderline or intermediate risk patients, the target is below 100 mg/dL. For high-risk patients, below 70 mg/dL. For those with established cardiovascular disease at very high risk, the target drops to below 55 mg/dL.

The underlying logic is cumulative exposure: lower LDL cholesterol maintained over longer periods translates into substantially greater protection against cardiovascular events. Blumenthal compared it to blood pressure management, where earlier and more sustained control yields outsized long-term benefits.

Lifestyle changes - healthy weight, physical activity, tobacco avoidance, good sleep - remain the first line of intervention. But the guideline explicitly recommends considering lipid-lowering medication earlier than previous versions suggested when lifestyle optimization does not bring numbers into range.

New tests to refine the picture

Three additional assessments are recommended in appropriate cases:

• Coronary artery calcium (CAC) scans for men 40 and older and women 45 and older at borderline or intermediate risk, when the result would influence whether to prescribe a statin. Any detectable calcium supports an LDL goal below 100 mg/dL.
• Lipoprotein(a), or Lp(a), should be measured at least once in every adult. Lp(a) is largely genetically determined and stable over a lifetime. Levels at or above 125 nmol/L carry roughly 1.4 times the long-term risk of heart attack or stroke; at 250 nmol/L, the risk at least doubles. Lifestyle changes barely move Lp(a), so repeat testing is generally unnecessary.
• Apolipoprotein B (apoB) measurement may better assess residual risk in patients with Type 2 diabetes, high triglycerides, or metabolic syndrome who have already met LDL-C goals.

Beyond statins

Statins remain the foundation of lipid-lowering therapy. When they are insufficient, the guideline recommends adding ezetimibe and/or bempedoic acid (an oral medication) or a PCSK9 monoclonal antibody (an injectable). Inclisiran, a newer injectable requiring less frequent dosing, is mentioned but not fully endorsed pending clinical trial results confirming that its LDL-lowering effect translates into fewer cardiac events.

For hypertriglyceridemia, lifestyle changes and statins remain primary, with additional therapies guided by individual ASCVD and pancreatitis risk.

Special populations

The guideline includes targeted recommendations for higher-risk groups: initiating therapy for those over 40 with chronic kidney disease, HIV, or diabetes; continuing therapy during cancer treatment unless contraindicated; and deferring most lipid drugs during conception, pregnancy, and lactation. Universal cholesterol screening is recommended for children ages 9 to 11 who have not been previously screened.

Risk enhancers - including family history, inflammatory conditions like lupus, South Asian or Filipino ancestry, early menopause, and gestational diabetes - can further refine individual risk scores beyond what standard calculators capture.

What this does not resolve

Guidelines are recommendations, not mandates. Implementation depends on clinicians adopting the PREVENT calculator, ordering Lp(a) tests, and having conversations about earlier pharmacotherapy with patients who may prefer to defer medication. Insurance coverage for CAC scans and newer non-statin therapies varies widely, which could limit access for the populations most likely to benefit.

The guideline also cannot address the fundamental challenge of adherence: roughly half of statin-eligible adults do not take them as prescribed, a problem no risk calculator can solve.